IMNM Valuation

Immunome Inc

Add to Watchlist

Advanced Chart

17.000

+0.93(5.787%)1D

IMNM Relative Valuation

IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMNM is overvalued; if below, it's undervalued.

Historical Valuation

Immunome Inc (IMNM) is now in the Fair zone, suggesting that its current forward PS ratio of 16.07 is considered Fairly compared with the five-year average of -5.55. The fair price of Immunome Inc (IMNM) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：16.07

Fair

-7.03

Trailing

Forward

-5.54

EV/EBITDA

Immunome Inc. (IMNM) has a current EV/EBITDA of -5.54. The 5-year average EV/EBITDA is -0.75. The thresholds are as follows: Strongly Undervalued below -3.71, Undervalued between -3.71 and -2.23, Fairly Valued between 0.73 and -2.23, Overvalued between 0.73 and 2.21, and Strongly Overvalued above 2.21. The current Forward EV/EBITDA of -5.54 falls within the Strongly Undervalued range.

-5.34

EV/EBIT

Immunome Inc. (IMNM) has a current EV/EBIT of -5.34. The 5-year average EV/EBIT is -3.59. The thresholds are as follows: Strongly Undervalued below -10.71, Undervalued between -10.71 and -7.15, Fairly Valued between -0.03 and -7.15, Overvalued between -0.03 and 3.54, and Strongly Overvalued above 3.54. The current Forward EV/EBIT of -5.34 falls within the Historic Trend Line -Fairly Valued range.

16.07

Immunome Inc. (IMNM) has a current PS of 16.07. The 5-year average PS is 118.90. The thresholds are as follows: Strongly Undervalued below -466.32, Undervalued between -466.32 and -173.71, Fairly Valued between 411.51 and -173.71, Overvalued between 411.51 and 704.12, and Strongly Overvalued above 704.12. The current Forward PS of 16.07 falls within the Historic Trend Line -Fairly Valued range.

-7.40

P/OCF

Immunome Inc. (IMNM) has a current P/OCF of -7.40. The 5-year average P/OCF is -3.69. The thresholds are as follows: Strongly Undervalued below -10.57, Undervalued between -10.57 and -7.13, Fairly Valued between -0.24 and -7.13, Overvalued between -0.24 and 3.20, and Strongly Overvalued above 3.20. The current Forward P/OCF of -7.40 falls within the Undervalued range.

-7.90

P/FCF

Immunome Inc. (IMNM) has a current P/FCF of -7.90. The 5-year average P/FCF is -3.64. The thresholds are as follows: Strongly Undervalued below -11.98, Undervalued between -11.98 and -7.81, Fairly Valued between 0.53 and -7.81, Overvalued between 0.53 and 4.70, and Strongly Overvalued above 4.70. The current Forward P/FCF of -7.90 falls within the Undervalued range.

Immunome Inc (IMNM) has a current Price-to-Book (P/B) ratio of 5.19. Compared to its 3-year average P/B ratio of 5.33 , the current P/B ratio is approximately -2.60% higher. Relative to its 5-year average P/B ratio of 4.46, the current P/B ratio is about 16.43% higher. Immunome Inc (IMNM) has a Forward Free Cash Flow (FCF) yield of approximately -16.60%. Compared to its 3-year average FCF yield of -15.87%, the current FCF yield is approximately 4.60% lower. Relative to its 5-year average FCF yield of -18.20% , the current FCF yield is about -8.77% lower.

5.19

P/B

Median3y

5.33

Median5y

4.46

-16.60

FCF Yield

Median3y

-15.87

Median5y

-18.20

Competitors Valuation Multiple

The average P/S ratio for IMNM's competitors is 20.06, providing a benchmark for relative valuation. Immunome Inc Corp (IMNM) exhibits a P/S ratio of 16.07, which is -19.90% above the industry average. Given its robust revenue growth of 69.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Dianthus Therapeutics Inc

Enliven Therapeutics Inc

23.42

1.18B

TRVI.O

Trevi Therapeutics Inc

Performance Decomposition

Market capitalization of IMNM increased by 25.46% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.36M to 4.02M.

The secondary factor is the P/E Change, contributed -15.12%to the performance.

Overall, the performance of IMNM in the past 1 year is driven by Revenue Growth. Which is more sustainable.

69.84%

2.36M → 4.02M

Revenue Growth

-29.26%

-1.53K → -1.08K

Margin Expansion

-15.12%

-6.82 → -5.79

P/E Change

25.46%